ConductScience.org, home

Paper42579268

Extended Venous Thromboembolism Prophylaxis After One-Anastomosis Gastric Bypass: A Three-Arm Randomized Trial of Enoxaparin Duration and Rivaroxaban.

Nageeb ME and 5 others. Obes Surg, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Extended Venous Thromboembolism Prophylaxis After One-Anastomosis Gastric Bypass: A Three-Arm Randomized Trial of Enoxaparin Duration and Rivaroxaban. Papers, record 42579268. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42579268

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Extended Venous Thromboembolism Prophylaxis After One-Anastomosis Gastric Bypass: A Three-Arm Randomized Trial of Enoxaparin Duration and Rivaroxaban.
PubMed
Journal
Obes Surg
PubMed
Year
2026
PubMed
Publication types
Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-15
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nageeb MEMohammed Elshwadfyhttps://orcid.org/0000-0003-3661-3610
2Ismail NSNagy Salah
3Mohamed AAAAbdelkarem Ahmed Abdelkarem
4Yacoub MMohamed
5Torfa KMKhaled Mosleh
6Shazly MNMohamed Nasr

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
EnoxaparinMajor topic
RivaroxabanMajor topic
Venous ThromboembolismMajor topic
Obesity, MorbidMajor topic
AnticoagulantsMajor topic
Gastric BypassMajor topic
Factor Xa InhibitorsMajor topic
Postoperative ComplicationsMajor topic
Humans
Female
Male
Adult
Middle Aged
Drug Administration Schedule
Treatment Outcome
Laparoscopy

Source PubMed

Download CSV of topics

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134860988Low-Molecular-Weight Heparin Prophylaxis Dosing: Is Weight an Issue?J Pharm Technol2016https://conductscience.org/library/papers/34860988PubMed
211451734Mechanism of action and pharmacology of unfractionated heparin.Arterioscler Thromb Vasc Biol2001https://conductscience.org/library/papers/11451734PubMed
338602603
Cumulative Incidence of Venous Thromboembolic Events In-Hospital, and at 1, 3, 6, and 12 Months After Metabolic and Bariatric Surgery: Systematic Review of 87 Studies and Meta-analysis of 2,731,797 Patients.
Obes Surg2024https://conductscience.org/library/papers/38602603PubMed
435844166Direct oral anticoagulants after bariatric surgery-What is the evidence?J Thromb Haemost2022https://conductscience.org/library/papers/35844166PubMed
528009739Who Should Get Extended Thromboprophylaxis After Bariatric Surgery?: A Risk Assessment Tool to Guide Indications for Post-discharge Pharmacoprophylaxis.Ann Surg2017https://conductscience.org/library/papers/28009739PubMed
632969260Prophylaxis with rivaroxaban after laparoscopic sleeve gastrectomy could reduce the frequency of portomesenteric venous thrombosis.Ann R Coll Surg Engl2020https://conductscience.org/library/papers/32969260PubMed
724022324Incidence of venous thromboembolism after bariatric surgery: a population-based cohort study.Obes Surg2013https://conductscience.org/library/papers/24022324PubMed
820888031The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.Thromb Res2011https://conductscience.org/library/papers/20888031PubMed
941226331The Interplay Between Obesity and Venous Thromboembolism: From Molecular Aspects to Clinical Issue.Int J Mol Sci2025https://conductscience.org/library/papers/41226331PubMed
1026713434Risk of Post-Discharge Venous Thromboembolism and Associated Mortality in General Surgery: A Population-Based Cohort Study Using Linked Hospital and Primary Care Data in England.PLoS One2015https://conductscience.org/library/papers/26713434PubMed
1126276933Postsurgical Inflammation as a Causative Mechanism of Venous Thromboembolism.Semin Thromb Hemost2015https://conductscience.org/library/papers/26276933PubMed
1240917200Obesity and Venous Thromboembolism: Mechanisms, Clinical Implications, and Prevention Strategies With a Focus on Bariatric Surgery.J Metab Bariatr Surg2025https://conductscience.org/library/papers/40917200PubMed
1335788047Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital: systematic review and network meta-analysis.BMJ2022https://conductscience.org/library/papers/35788047PubMed
1435620356Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis.Eur Cardiol2022https://conductscience.org/library/papers/35620356PubMed
1531285809Patient compliance with deep vein thrombosis prophylaxis after total hip and total knee arthroplasty.Hematol Rep2019https://conductscience.org/library/papers/31285809PubMed
1621421182Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence Participants: analysis of the Bariatric Outcomes Longitudinal Database.Surg Obes Relat Dis2011https://conductscience.org/library/papers/21421182PubMed
1728159600Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance.Am J Med2017https://conductscience.org/library/papers/28159600PubMed
1838266535Pharmacokinetics of direct oral anticoagulants after bariatric surgery: A retrospective cohort study.Thromb Res2024https://conductscience.org/library/papers/38266535PubMed
1938957028European guidelines on peri-operative venous thromboembolism prophylaxis: first update.: Chapter 10: Surgery in the obese patient.Eur J Anaesthesiol2024https://conductscience.org/library/papers/38957028PubMed
2037227726Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery: A Randomized Clinical Trial.JAMA Netw Open2023https://conductscience.org/library/papers/37227726PubMed

See all 23 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42579268

GET https://conductscience.org/api/papers/v1/42579268/references?page=2